Related Experiment Videos
A recombinant vaccine for Lyme disease
R Wallich1, M D Kramer, M M Simon
1Institut für Immunologie und Serologie, Universität Heidelberg, Germany.
Behring Institute Mitteilungen
|December 1, 1994
Summary
Researchers developed a promising vaccine targeting outer surface lipoprotein A (OspA) from Borrelia burgdorferi. This OspA-based vaccine candidate is safe, immunogenic, and elicits protective immunity against Lyme disease in early clinical trials.
Area of Science:
- Immunology
- Vaccinology
- Microbiology
Background:
- Lyme borreliosis is a significant tick-borne illness caused by Borrelia burgdorferi.
- Outer surface lipoproteins A and B (OspA and OspB) are key targets on the spirochete.
- Developing an effective vaccine is crucial for clinical use.
Purpose of the Study:
- To investigate OspA and OspB as targets for a Lyme disease vaccine.
- To evaluate the protective immunity induced by OspA in preclinical models.
- To assess the safety and immunogenicity of a recombinant OspA vaccine candidate in human trials.
Main Methods:
- Induction of immune sera using native and recombinant OspA.
- Passive transfer of protection in severe combined immunodeficiency (SCID) mice.
- Phase I and II clinical trials to assess safety and efficacy.
Main Results:
- Monospecific immune sera against OspA conferred passive protection in SCID mice.
- The recombinant OspA vaccine candidate demonstrated safety and immunogenicity.
- The vaccine elicited borreliacidal antibodies in human participants.
Conclusions:
- Recombinant OspA is a viable vaccine candidate for Lyme borreliosis.
- The vaccine shows promise for preventing Lyme disease.
- Further clinical development is warranted based on promising trial results.